Patheon NV, the Dutch maker of drug ingredients that filed for a U.S. initial public offering more than a year ago, may move ahead with the listing this month, a person with knowledge of the matter said.
The company, which is backed by private equity firm JLL Partners, may set terms and begin its roadshow as soon as next week, said the person, who asked not to be identified because the information is private. It plans to raise more than $500 million in the IPO, the person said.
Patheon filed its initial prospectus in June 2015 with a placeholder of $100 million, an amount used to calculate fees that often changes. Proceeds from the deal will be used to pay down debt, the prospectus shows.
JLL Partners and Netherlands-based Royal DSM NV, the world’s largest producer of vitamins, are listed in the prospectus under principal and selling shareholders.
A spokesman for JLL declined to comment, while a representative of Patheon didn’t immediately respond to a request for comment.
Patheon posted net income of $138.4 million on sales of $1.8 billion in the year ended Oct. 31. That compares with a net loss of $119 million on revenue of $1.5 billion in fiscal 2014.
Another health-care company, InVentiv Group Holdings Inc., which is backed by Thomas H. Lee Partners, filed to go public in April. It’s also exploring a possible sale, people with knowledge of the matter said in June.